|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPOX |
Gene summary for PPOX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPOX | Gene ID | 5498 |
| Gene name | protoporphyrinogen oxidase | |
| Gene Alias | PPO | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0006725 | UniProtAcc | P50336 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5498 | PPOX | LZE4T | Human | Esophagus | ESCC | 1.49e-04 | 9.67e-02 | 0.0811 |
| 5498 | PPOX | LZE7T | Human | Esophagus | ESCC | 8.39e-08 | 3.06e-01 | 0.0667 |
| 5498 | PPOX | LZE20T | Human | Esophagus | ESCC | 3.28e-03 | 8.58e-02 | 0.0662 |
| 5498 | PPOX | LZE22T | Human | Esophagus | ESCC | 4.99e-02 | 2.07e-01 | 0.068 |
| 5498 | PPOX | LZE24T | Human | Esophagus | ESCC | 6.31e-13 | 2.40e-01 | 0.0596 |
| 5498 | PPOX | LZE6T | Human | Esophagus | ESCC | 3.59e-03 | 1.75e-01 | 0.0845 |
| 5498 | PPOX | P1T-E | Human | Esophagus | ESCC | 3.77e-06 | 3.20e-01 | 0.0875 |
| 5498 | PPOX | P2T-E | Human | Esophagus | ESCC | 2.35e-11 | 2.70e-01 | 0.1177 |
| 5498 | PPOX | P4T-E | Human | Esophagus | ESCC | 3.43e-13 | 2.22e-01 | 0.1323 |
| 5498 | PPOX | P5T-E | Human | Esophagus | ESCC | 6.66e-05 | 7.52e-02 | 0.1327 |
| 5498 | PPOX | P8T-E | Human | Esophagus | ESCC | 4.87e-07 | 1.30e-01 | 0.0889 |
| 5498 | PPOX | P9T-E | Human | Esophagus | ESCC | 1.04e-07 | 2.08e-01 | 0.1131 |
| 5498 | PPOX | P10T-E | Human | Esophagus | ESCC | 3.94e-17 | 2.67e-01 | 0.116 |
| 5498 | PPOX | P11T-E | Human | Esophagus | ESCC | 8.10e-09 | 3.31e-01 | 0.1426 |
| 5498 | PPOX | P12T-E | Human | Esophagus | ESCC | 4.83e-15 | 1.86e-01 | 0.1122 |
| 5498 | PPOX | P15T-E | Human | Esophagus | ESCC | 3.88e-09 | 1.30e-01 | 0.1149 |
| 5498 | PPOX | P16T-E | Human | Esophagus | ESCC | 3.16e-15 | 2.59e-01 | 0.1153 |
| 5498 | PPOX | P17T-E | Human | Esophagus | ESCC | 2.27e-03 | 1.77e-01 | 0.1278 |
| 5498 | PPOX | P19T-E | Human | Esophagus | ESCC | 1.23e-03 | 2.69e-01 | 0.1662 |
| 5498 | PPOX | P20T-E | Human | Esophagus | ESCC | 7.47e-14 | 2.74e-01 | 0.1124 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:00067791 | Esophagus | ESCC | porphyrin-containing compound biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
| GO:00330141 | Esophagus | ESCC | tetrapyrrole biosynthetic process | 23/8552 | 31/18723 | 1.20e-03 | 5.88e-03 | 23 |
| GO:00461482 | Esophagus | ESCC | pigment biosynthetic process | 40/8552 | 62/18723 | 2.14e-03 | 9.54e-03 | 40 |
| GO:00067832 | Esophagus | ESCC | heme biosynthetic process | 20/8552 | 27/18723 | 2.61e-03 | 1.11e-02 | 20 |
| GO:00330132 | Esophagus | ESCC | tetrapyrrole metabolic process | 37/8552 | 59/18723 | 6.23e-03 | 2.29e-02 | 37 |
| GO:00424401 | Esophagus | ESCC | pigment metabolic process | 50/8552 | 84/18723 | 7.34e-03 | 2.64e-02 | 50 |
| GO:00421681 | Esophagus | ESCC | heme metabolic process | 27/8552 | 42/18723 | 1.16e-02 | 3.90e-02 | 27 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPOX | SNV | Missense_Mutation | c.1021N>T | p.Pro341Ser | p.P341S | P50336 | protein_coding | tolerated(0.62) | benign(0.019) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | CR | ||
| PPOX | SNV | Missense_Mutation | c.1033N>C | p.Gly345Arg | p.G345R | P50336 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| PPOX | SNV | Missense_Mutation | novel | c.266N>A | p.Gly89Glu | p.G89E | P50336 | protein_coding | tolerated(0.27) | probably_damaging(0.985) | TCGA-AC-A3HN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPOX | SNV | Missense_Mutation | novel | c.808G>A | p.Val270Ile | p.V270I | P50336 | protein_coding | tolerated(0.81) | benign(0.042) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PPOX | SNV | Missense_Mutation | c.448N>A | p.Ala150Thr | p.A150T | P50336 | protein_coding | tolerated(0.32) | benign(0) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PPOX | SNV | Missense_Mutation | novel | c.469G>A | p.Glu157Lys | p.E157K | P50336 | protein_coding | deleterious(0.04) | benign(0.189) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| PPOX | insertion | Nonsense_Mutation | novel | c.370_371insGCTAGTTTTTGTATTTTTAGTAGAGATGGGGTTTCACCAT | p.Lys124SerfsTer2 | p.K124Sfs*2 | P50336 | protein_coding | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| PPOX | insertion | Frame_Shift_Ins | novel | c.732_733insC | p.Thr245HisfsTer2 | p.T245Hfs*2 | P50336 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PPOX | insertion | Nonsense_Mutation | novel | c.733_734insAAGTGCTGGGATTACAGGCGTGAGCCACCACGCCCGACCTGC | p.Thr245delinsLysValLeuGlyLeuGlnAlaTerAlaThrThrProAspLeuPro | p.T245delinsKVLGLQA*ATTPDLP | P50336 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| PPOX | insertion | Nonsense_Mutation | novel | c.1418_1419insTTAGGTGATGCTGGGAGGTTCCTGGTTACAGACACTGG | p.Glu474Ter | p.E474* | P50336 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5498 | PPOX | DRUGGABLE GENOME, ENZYME | Aminolevulinic Acid Hydrochloride | |||
| 5498 | PPOX | DRUGGABLE GENOME, ENZYME | givosiran | GIVOSIRAN | ||
| 5498 | PPOX | DRUGGABLE GENOME, ENZYME | Givosiran | GIVOSIRAN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |